ATYR

aTYR PHARMA INC

Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001339970 Biotech & Drug Discovery

$0.1530 −0.01 (−7.27%)

Oct 26 4:00 PM ET · prev $0.1650

Market cap

$16.7M

Nano cap

Median target

$3.00

+1861% · range $1.00–7.00

Next earnings

Nov 5

in 9 days · EPS est. −$0.10

1 year

−84.3%

from $0.9730 · Oct 27

30 days

−48.7%

from $0.2980

52-week range

$0.1530–1.05

at the low

Avg volume 20D

1.95M

shares / day

Short interest

🔒 Subscribers only

Insider net

+$43.4K

1 buyer · 3 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BEARISH 4 reports · 90 days

Balance 2 bearish · 0 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 3/4 ·Next Earnings date, Nov 5, 2026

Strongest NEUTRAL aTyr Pharma announced a research collaboration with Albert Einstein College of Medicine to further develop…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S Feb 4 3 insiders sell $6.3K at $0.9760
R Mar 5 aTyr Pharma reported full-year 2025 financial results and provided a…
R May 11 aTyr Pharma announced it will proceed with a new Phase 3 trial (C-00…
A May 20 Freedom Broker upgrades
B May 27 1 insider buy $49.6K at $0.4963
R Jun 8 aTyr Pharma received a Nasdaq deficiency notice on December 4, 2025…
R Aug 7 aTyr Pharma reported Q2 2026 results alongside a major corporate res…

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $49.6K at an average $0.4963. 3 insiders sold $6.3K. Price is 69% below their cost.
InstitutionsMIXED

Q2 2026: 13 added (0 new), 15 trimmed or exited.
EstimatesRISING

Current-quarter EPS estimate −$0.133 → −$0.100 over 90 days. 4 up, 0 down in 30 days.
TrendDOWNTREND

58% below its 50-day average. New closing low $0.1530 on Oct 26.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
FMR LLC	NEAR_EXIT	2,471,418	$1.5M
BlackRock, Inc.	TRIM	1,827,332	$1.1M
JANE STREET GROUP, LLC	DOUBLED	1,721,297	$1.0M
UBS Group AG	TRIM	1,531,151	$914.1K
CITADEL ADVISORS LLC	DOUBLED	1,242,067	$741.3K
GEODE CAPITAL MANAGEMENT, LLC	TRIM	1,177,020	$702.7K
MILLENNIUM MANAGEMENT LLC	TRIM	656,051	$391.5K
GOLDMAN SACHS GROUP INC	DOUBLED	641,208	$382.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026

12-month targets · 7 analysts

$0.1530 $1.00 $3.00 $7.00

Price is below the lowest target. Median implies +1861%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
May 20, 2026	Freedom Broker UPGRADE	UPGRADE	Buy

Insider ledger

Form 4

$49.6K

bought · 1 insider

$6.3K

sold · 3 insiders

−69.2%

vs their $0.4963 cost

Date	Insider	Type	Value
Oct 1, 2026	Yaras Brandon Chief Financial Officer	AWARD	410,000 sh
May 27, 2026	SCHIMMEL PAUL Director	BUY	$49.6K
May 11, 2026	SCHIMMEL PAUL Director	AWARD	50,000 sh
May 11, 2026	Zaknoen Sara Director	AWARD	50,000 sh
May 11, 2026	Lucas Svetlana Director	AWARD	50,000 sh
May 11, 2026	Gross Jane A Director	AWARD	50,000 sh
May 11, 2026	BENEVICH ERIC Director	AWARD	50,000 sh
May 11, 2026	Coughlin Timothy Director	AWARD	50,000 sh

Earnings setup

Estimates

Nov 5

reports in 9 days

−$0.10

EPS estimate, this quarter

+25%

estimate change, 90 days

4↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.133

90d

−$0.141

60d

−$0.100

30d

−$0.100

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.10	-$0.12–-$0.08	+0.0%	$0.00
Next Q	-$0.09	-$0.16–-$0.06	+0.0%	$0.00
Current FY	-$0.41	-$0.50–-$0.36	-1.0%	$0.00
Next FY	-$0.44	-$0.93–-$0.16	-0.3%	$0.00